je.st
news
Tag: mercks
Drugmaker Merck's Q4 profit, sales fall due to generic competition,...
2014-02-05 15:23:14| Biotech - Topix.net
Merck & Co. reported a 14 per cent decline in fourth-quarter profit as generic competition continued to cut into sales of one-time blockbuster medicines, and unfavourable currency exchange rates reduced overseas revenue.
Merck Statement on FDA Advisory Committee for Vorapaxar, Merck's Investigational Antiplatelet Medicine
2014-01-16 22:12:41| Biotech - Topix.net
Merck , known as MSD outside the United States and Canada, today said it was pleased with the U.S. Food and Drug Administration 's Cardiovascular and Renal Drugs Advisory Committee's recommendation for approval of vorapaxar.
Tags: statement
medicine
committee
advisory
Merck Statement on FDA Advisory Committee for Vorapaxar, Mercks Investigational Antiplatelet Medicine
2014-01-16 00:59:00| Merck.com - Research & Development News
Dateline City: WHITEHOUSE STATION, N.J. WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today said it was pleased with the U.S. Food and Drug Administration (FDA)s Cardiovascular and Renal Drugs Advisory Committees recommendation for approval of vorapaxar. Vorapaxar is the companys investigational antiplatelet medicine for the reduction of atherothrombotic events, when added to standard of care, in patients with a history of heart attack and no history of stroke or transient ischemic attack. Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558orPatrick Witmer, 267-305-4910orInvestors:Carol Ferguson, 908-423-4465orJustin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: statement
medicine
committee
advisory
Merck Statement on FDA Advisory Committee for GRASTEK (Timothy Grass Pollen Allergen Extract), Mercks Investigational Sublingual Allergy Immunotherapy Tablet
2013-12-13 01:17:00| Merck.com - Product News
Dateline City: WHITEHOUSE STATION, N.J. WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today issued the following statement after the conclusion of the Allergenic Products Advisory Committee of the U.S. Food and Drug Administration (FDA) meeting to discuss GRASTEK (Timothy grass pollen allergen extract). Language: English Contact: MerckMedia:Pamela Eisele, 908-423-5042orRobert Consalvo, 908-423-6595orInvestors:Carol Ferguson, 908-423-4465orJustin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: statement
committee
advisory
grass
FDA panel says Merck's allergy drug effective
2013-12-13 00:03:44| Biotech - Topix.net
A panel of experts advising the U.S. Food and Drug Administration said an oral drug made by Merck & Co was effective in treating grass pollen allergy but expressed concerns about the drug's safety in children.
Tags: effective
panel
drug
allergy
Sites : [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] next »